Most Read Articles
Pearl Toh, 07 Aug 2018
A home-based, self-applied wearable electrocardiogram (ECG) patch facilitates diagnosis of atrial fibrillation (AF) among high-risk individuals, according to the mSToPS* trial.
Roshini Claire Anthony, 2 days ago

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

5 days ago

Fungal microbiome, also called the mycobiome, appears to be highly variable in patients with well-characterized fungal diseases, a recent study has shown. Moreover, severe asthmatics have the highest fungal loads, along with those receiving steroid and antifungal therapy.

Tristan Manalac, 3 days ago
The risk of complicated appendicitis is lower in children with IgE-mediated allergy, according to a recent study.

Early RAAS blockade improves short-, long-term renal outcomes in SLE patients with aPLN

23 May 2018
Would your patient really want to know where it came from?

Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

No significant difference was observed in demographic data, laboratory findings and renal histology by the time of kidney biopsy between the RASI and non-RASI groups. However, the former showed higher proteinuria levels than the latter (5.2; 2.8–8.8 vs 1.9; 0.6–2.8 g/day; p=0.005) and higher prevalence of hypertension (75 percent vs 29 percent; p=0.001).

At 12 months after kidney biopsy, there was no significant between-group difference in estimated glomerular filtration rate (eGFR), mean arterial pressure and proteinuria. The RASI group showed significantly higher improvement ratio of eGFR vs the non-RASI group (26 percent; –5 to 86 percent vs –2 percent; –20 to 20; p=0.028). Beyond 12 months, the rate of change in eGFR was similar between the two groups.

Furthermore, kidney disease progression developed in four patients (23 percent) in the non-RASI group and three (8 percent) in the RASI group during a mean follow-up of 80 months. Early RAAS blockade significantly reduced the risk of kidney disease progression (hazard ratio, 0.11; 0.02–0.59; p=0.010).

The two groups had comparable proteinuria and hypertension controls.

To assess the renal protective effects of RAAS with RASI, the investigators analysed medical data of 57 SLE patients with biopsy-proven aPLN. Early RAAS blockade was defined as administration of RASI within 3 months after kidney biopsy and continued for ≥12 months.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 07 Aug 2018
A home-based, self-applied wearable electrocardiogram (ECG) patch facilitates diagnosis of atrial fibrillation (AF) among high-risk individuals, according to the mSToPS* trial.
Roshini Claire Anthony, 2 days ago

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

5 days ago

Fungal microbiome, also called the mycobiome, appears to be highly variable in patients with well-characterized fungal diseases, a recent study has shown. Moreover, severe asthmatics have the highest fungal loads, along with those receiving steroid and antifungal therapy.

Tristan Manalac, 3 days ago
The risk of complicated appendicitis is lower in children with IgE-mediated allergy, according to a recent study.